Fiche publication
Date publication
décembre 2019
Journal
European journal of medicinal chemistry
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BOISBRUN Michel
,
Pr FLAMENT Stéphane
,
Dr MAZERBOURG Sabine
,
Pr GRANDEMANGE Stéphanie
Tous les auteurs :
Dupommier D, Muller C, Comoy C, Mazerbourg S, Bordessa A, Piquard E, Pawlak M, Piquard F, Martin H, De Fays E, Grandemange S, Flament S, Boisbrun M
Lien Pubmed
Résumé
Breast cancer is a major medical threat which cannot be sufficiently addressed by current therapies because of spontaneous or acquired treatment resistance. Besides, triple-negative breast cancer (TNBC) tumors do not respond to targeted therapies, thus new therapeutic strategies are needed. In this context, we designed and prepared new desulfured troglitazone (TGZ)-derived molecules and evaluated them in vitro for their anti-proliferative activity, with a special focus on triple-negative breast cancer cell lines. Optimization of the synthetic strategies and deracemization of the lead compound were performed to give highly active compound 10 with low-micromolar potency. Further studies revealed that this compound triggers apoptosis rather than cell cycle arrest as observed with TGZ.
Mots clés
Apoptosis, Breast cancer, Chromane, Deracemization, Lipase, Troglitazone
Référence
Eur J Med Chem. 2019 Dec 4;187:111939
